Global Malaria Vaccines Market, By Agent (Plasmodium Falciparum, Plasmodium Vivax, Anopheles Species), Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Malaria's prevalence in tropical nations has been a source of concern for the entire world, causing millions of fatalities during the last ten years. Vaccine development is an essential component of effective interventional control. In recent years, there has been a lot of study into new vaccine options. A diversified pipeline has been studied based on ongoing malaria life-cycle research. Understanding the biology of the deadly human malaria parasites Plasmodium falciparum and Plasmodium vivax is critical for expanding opportunities in the malaria vaccine industry. New options in the malaria vaccine business have opened up thanks to generations of pre-erythrocytic vaccinations. This has sparked a flurry of interest from biotech firms. RTS, S/AS01 (RTS,S) is the most thoroughly investigated vaccine option for P. falciparum malaria prophylaxis.
Data Bridge Market Research analyses that the malaria vaccines market was valued at USD 1,852.38 million in 2021 and is expected to reach USD 18,913.86 million by 2029, registering a CAGR of 33.70% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Agent (Plasmodium Falciparum, Plasmodium Vivax, Anopheles Species), Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Actiza Pharmaceutical Private Limited (India), AdvaCare Pharma (U.S.), Ipca Laboratories Ltd. (India), Bliss GVS Pharma Ltd. (India), GeoVax (U.S.), Sumaya Biotech (Germany), VLP Therapeutics (U.S.), OSIVAX (France), AJANTA PHARMA (India), Strides Pharma Science Limited (India), Mylan N.V. (U.S.), Zydus Cadila (India), Cipla Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), Hikma Pharmaceuticals PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Taj Pharmaceuticals Limited. (India), Lupin (India), Novartis AG (Switzerland), Pfizer Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Malaria vaccines are treatments that protect against malaria, a mosquito-borne infectious disease. Malaria, commonly known as plasmodium infection, is spread via the bite of infected female anopheles mosquitos. Chills, fever, and sweating are symptoms of this long-term sickness. These vaccines can be given in various ways, including intramuscular, subcutaneous, and intradermal injections. The World Health Organization (WHO) recommends that these vaccinations be used in places where there is a high burden of disease and malaria transmission.
Malaria Vaccines Market Dynamics
Drivers
- Rise in the prevalence of malaria in low-income countries
The rise in prevalence of malaria in low-income countries is anticipated to flourish the market's growth rate. Malaria is a life-threatening infectious disease spread by female Anopheles mosquitoes and caused by the Plasmodium parasite. The malaria epidemic is spreading, and climate change is making it easier for mosquito vectors to thrive. According to the WHO, there were around 229 million malaria infections and 409,000 fatalities worldwide in 2019. Malaria has primarily plagued tropical areas such as Africa, Asia, Central America, and South America. In addition, malaria is most common in Africa, Southeast Asia, the Eastern Mediterranean, and the Western Pacific.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of malaria vaccines market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, increases in number of patient awareness level as well as government initiatives and growing application of malaria vaccines in various therapeutic conditions will expand the malaria vaccines market. Additionally, the implementation of favourable government policies to promote global health and medical science advancement are estimated to enhance the market’s growth rate.
Opportunities
- Increase in the number of research and development activities
The malaria vaccines market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the malaria vaccines market growth. Over the last few years, researchers have significantly improved vaccine-induced efficacy. RTS, S/AS01 has been the focus of a number of clinical investigations. Recent experiments in Sub-Saharan Africa have fueled such progress. RTS, S has being examined by the WHO for use as a malaria control tool in addition to preventive, diagnostic, and therapeutic strategies. It is the only malaria vaccine that has been shown to be effective, especially in young African children.
Moreover, increase in the number of emerging markets and new product launches will further provide beneficial opportunities for the malaria vaccines market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with drug development and distribution will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the malaria vaccines market. Additionally, lack of awareness among people and technological challenge in developing vaccine will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This malaria vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the malaria vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Malaria vaccines market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Malaria Vaccines Market
The demand for the medicine has increased as a result of the COVID-19 outbreak, and the market has grown significantly as a result. The effectiveness of malaria vaccines in treating patients with coronavirus infection (COVID-19) has recently received attention. Chloroquine has been shown to inhibit SARS-CoV-2 in vitro, according to Chinese reports. The medicine was found to be highly effective in treating patients with COVID-19. The coronavirus drug malaria vaccines is believed to be a viable possible therapy (COVID 19). The US Food and Drug Administration (FDA) has approved malaria vaccines for use in treating coronavirus infection as an emergency treatment.
Recent Development
- In October 2021, GlaxoSmithKline (GSK) plc welcomes and applauds the World Health Organization's (WHO) proposal to expand the use of GSK's RTS,S malaria vaccine in children living in Sub-Saharan Africa and other locations with moderate to high transmission, as defined by WHO. RTS,S is the first and only malaria vaccine to be shown to reduce malaria in children in key long-term clinical trials dramatically. The vaccine is the result of more than 30 years of work by GSK, PATH, and other collaborators.
Global Malaria Vaccines Market Scope
The malaria vaccines market is segmented on the basis of route of administration, agent, vaccine type, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Agent
- Plasmodium Falciparum
- Plasmodium Vivax
- Anopheles Species
Vaccine Type
- Pre-Erythrocytic
- Erythrocytic
- Multi-antigen
- Others
Route of Administration
- Intramuscular
- Subcutaneous
- Intradermal
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Malaria Vaccines Market Regional Analysis/Insights
The malaria vaccines market is analysed and market size insights and trends are provided by country, agent, route of administration, vaccine type, end-users and distribution channel as referenced above.
The countries covered in the malaria vaccines market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the malaria vaccines market because of the presence of key manufacturers of the product and well-established healthcare infrastructure in this region. Additionally, high research and development expenditure and presence of skilled professionals will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022 to 2029 due to increased government awareness programs and rising healthcare expenditure in this region. Also, growing number of generic drugs will further cushion the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Malaria Vaccines Market Share Analysis
The malaria vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to malaria vaccines market.
Some of the major players operating in the malaria vaccines market are:
- Actiza Pharmaceutical Private Limited (India)
- AdvaCare Pharma (U.S.)
- Ipca Laboratories Ltd. (India)
- Bliss GVS Pharma Ltd. (India)
- GeoVax (U.S.)
- Sumaya Biotech (Germany)
- VLP Therapeutics (U.S.)
- OSIVAX (France)
- AJANTA PHARMA (India)
- Strides Pharma Science Limited (India)
- Mylan N.V. (U.S.)
- Zydus Cadila (India)
- Cipla Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Sanofi (France)
- Hikma Pharmaceuticals PLC (U.K.)
- Amneal Pharmaceuticals LLC. (U.S.)
- Taj Pharmaceuticals Limited. (India)
- Lupin (India)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
SKU-